CD22 and diffuse large B-cell lymphoma: However, in nuclear medicine applications, DLBCL cells targeted by anti-CD22 antibodies are exposed to variable circulating antibody concentrations in the course of treatment, due to the mobilization of antibodies on healthy B cells and DLBCL cells, and due to antibody catabolism that progressively decreases the concentration of MAb in blood.